On Tuesday, shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) marked $49.23 per share versus a previous $45.31 closing price. With having a 8.65% gain, an insight into the fundamental values of Agios Pharmaceuticals, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. AGIO showed a rise of 3.10% within its YTD performance, with highs and lows between $28.36 – $68.94 during the period of 52 weeks, compared to the simple moving average of 10.78% in the period of the last 200 days.
Cantor Fitzgerald equity researchers changed the status of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) shares to a “Overweight” rating in the report published on November 26th, 2019. Other analysts, including Guggenheim, also published their reports on AGIO shares. Guggenheim repeated the rating from the previous report, marking AGIO under “Buy” rating, in the report published on September 23rd, 2019. Additionally, AGIO shares got another “Neutral” rating from Goldman, setting a target price of $55 on the company’s shares, according to the report published in May 23rd, 2019. On February 15th, 2019, SVB Leerink Upgrade an Outperform rating and increased its price target to $80. On the other hand, Leerink Partners Initiated the “Mkt Perform” rating for AGIO shares, as published in the report on September 25th, 2018. Citigroup seems to be going bullish on the price of AGIO shares, based on the price prediction for AGIO, indicating that the shares will jump to $117, giving the shares “Buy” rating based on their report from May 23rd, 2018. Another “Outperform” rating came from Credit Suisse, providing a prediction for $117 price target according to the report published in April 11th, 2018.
The present dividend yield for AGIO owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. In addition, the growth of sales from quarter to quarter is recording 71.10%, hinting the company’s progress in the upcoming progress.
In order to gain a clear insight on the performance of Agios Pharmaceuticals, Inc. (AGIO) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of -70.10% is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at 5.20 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.
Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while AGIO is currently recording an average of 924.58K in volumes. The volatility of the stock on monthly basis is set at 3.87%, while the weekly volatility levels are marked at 5.61%with 0.24% of gain in the last seven days. Additionally, long-term investors are predicting the target price of $65.09, indicating growth from the present price of $49.23, which can represent yet another valuable research and analysis points that can help you decide whether to invest in AGIO or pass.What to Look for When Analyzing Agios Pharmaceuticals, Inc. Shares?
Agios Pharmaceuticals, Inc. (AGIO) is based in the USA and it represents one of the well-known company operating with Healthcare sector. If you wish to compare AGIO shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of for Agios Pharmaceuticals, Inc., while the value can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value -6.85 is supported by the yearly ESP growth of 10.80%.
Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 2.90%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts 96.70% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.Are Institutional Investors Increasing Stakes in AGIO Shares?
It appears that more than several institutional investors and hedge funds decided to increase stakes in AGIO in the recent period. That is how Fidelity Management & Research Co now has an increase position in AGIO by 0.07% in the first quarter, owning 8.8 million shares of AGIO stocks, with the value of $420.12 million after the purchase of an additional 6,232 shares during the last quarter. In the meanwhile, Wellington Management Co. LLP also increased their stake in AGIO shares changed 18.80% in the first quarter, which means that the company now owns 7.98 million shares of company, all valued at $380.85 million after the acquisition of additional 1,262,220 shares during the last quarter.
The Vanguard Group, Inc. acquired a new position in Agios Pharmaceuticals, Inc. during the first quarter, with the value of $227.2 million, and Capital Research & Management Co. increased their stake in the company’s shares by 42.09% in the first quarter, now owning 1,371,522 shares valued at $221.08 million after the acquisition of the additional 4.63 million shares during the last quarter. In the end, Bellevue Asset Management AG increased their position by 1.27% during the first quarter, now owning 3.57 million AGIO shares, now holding the value of $170.54 million in AGIO with the purchase of the additional 443,420 shares during the period of the last quarter. At the present, 96.70% of AGIO shares are in the ownership of institutional investors.